219 related articles for article (PubMed ID: 22333523)
1. Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis.
Tsigkaropoulou E; Peppa M; Zompola C; Rizos E; Xelioti I; Chatziioannou S; Filippopoulou A; Lykouras L
Gend Med; 2012 Feb; 9(1):56-60. PubMed ID: 22333523
[TBL] [Abstract][Full Text] [Related]
2. Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma.
Freeman B; Levy W; Gorman JM
J Psychiatr Pract; 2007 Mar; 13(2):120-4. PubMed ID: 17414690
[No Abstract] [Full Text] [Related]
3. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis.
Broekhof R; Gosselink MJ; Pijl H; Giltay EJ
Gen Hosp Psychiatry; 2012; 34(2):209.e1-3. PubMed ID: 21872335
[TBL] [Abstract][Full Text] [Related]
4. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
Tollin SR
J Endocrinol Invest; 2000 Dec; 23(11):765-70. PubMed ID: 11194712
[TBL] [Abstract][Full Text] [Related]
5. Major depressive disorder induced by prolactinoma--a case report.
Liao WT; Bai YM
Gen Hosp Psychiatry; 2014; 36(1):125.e1-2. PubMed ID: 24182617
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole reduces serum prolactin in a woman with prolactinoma and acute psychosis.
Sheldrick AJ; Gründer G
Pharmacopsychiatry; 2008 Jul; 41(4):160. PubMed ID: 18651348
[No Abstract] [Full Text] [Related]
7. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia.
Hoffer ZS; Roth RL; Mathews M
Psychosomatics; 2009; 50(4):317-24. PubMed ID: 19687170
[TBL] [Abstract][Full Text] [Related]
8. Management of psychosis associated with a prolactinoma: case report and review of the literature.
Ali S; Miller KK; Freudenreich O
Psychosomatics; 2010; 51(5):370-6. PubMed ID: 20833935
[TBL] [Abstract][Full Text] [Related]
9. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
[TBL] [Abstract][Full Text] [Related]
10. Concomitant Cushing's Disease and Marked Hyperprolactinemia: Response to a Dopamine Receptor Agonist.
Shiraishi J; Koyama H; Shirakawa M; Ishikura R; Okazaki H; Kurajoh M; Shoji T; Moriwaki Y; Yamamoto T; Namba M
Intern Med; 2016; 55(8):935-41. PubMed ID: 27086808
[TBL] [Abstract][Full Text] [Related]
11. [Current diagnosis and treatment of hyperprolactinemia].
Melgar V; Espinosa E; Sosa E; Rangel MJ; Cuenca D; Ramírez C; Mercado M
Rev Med Inst Mex Seguro Soc; 2016; 54(1):111-21. PubMed ID: 26820213
[TBL] [Abstract][Full Text] [Related]
12. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).
Kelly DL; Wehring HJ; Earl AK; Sullivan KM; Dickerson FB; Feldman S; McMahon RP; Buchanan RW; Warfel D; Keller WR; Fischer BA; Shim JC
BMC Psychiatry; 2013 Aug; 13():214. PubMed ID: 23968123
[TBL] [Abstract][Full Text] [Related]
13. Osteopenia in children and adolescents with hyperprolactinemia.
Galli-Tsinopoulou A; Nousia-Arvanitakis S; Mitsiakos G; Karamouzis M; Dimitriadis A
J Pediatr Endocrinol Metab; 2000 Apr; 13(4):439-41. PubMed ID: 10777000
[TBL] [Abstract][Full Text] [Related]
14. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
[TBL] [Abstract][Full Text] [Related]
16. Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia--a case report with a review of the literature.
Konopelska S; Quinkler M; Strasburger CJ; Ventz M
J Clin Psychopharmacol; 2008 Feb; 28(1):120-2. PubMed ID: 18204364
[No Abstract] [Full Text] [Related]
17. Approach to the Patient With Prolactinoma.
Auriemma RS; Pirchio R; Pivonello C; Garifalos F; Colao A; Pivonello R
J Clin Endocrinol Metab; 2023 Aug; 108(9):2400-2423. PubMed ID: 36974474
[TBL] [Abstract][Full Text] [Related]
18. Management of a patient with schizophrenia and underlying pituitary macroadenoma.
Ng KW; Lee J; Swapna V
Ann Acad Med Singap; 2010 Nov; 39(11):868-9. PubMed ID: 21165528
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
[TBL] [Abstract][Full Text] [Related]
20. Cabergoline-induced psychotic exacerbation in schizophrenic patients.
Chang SC; Chen CH; Lu ML
Gen Hosp Psychiatry; 2008; 30(4):378-80. PubMed ID: 18585544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
